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CASE REPORT
Toxic epidermal necrolysis (TEN) and Stevens-
Johnson syndrome (SJS) are rare but life-
threatening skin and mucocutaneous disorders
that are usually drug-induced.1,2 Many different
drugs can cause TEN, including anticonvulsants,
nonsteroidal anti-inflammatory drugs, allopurinol,
sulphonamides, and antibiotics.2 TEN is character-
ized by extensive blistering, full-thickness necrosis,
and destruction of the epidermis. Recent studies
suggest that TEN and SJS are the same disease
spectrum that can present with differences in sever-
ity and area of involvement.3 SJS is less extensive
and affects less than 10% of the body surface area
(BSA), whereas TEN involves more than 30% BSA.
The mortality rate of SJS is up to 5%, while the
mortality among patients with TEN may surpass
30%. The pathogenesis of these diseases has not
yet been established. Dysregulation of immuno-
logic reaction is thought to be one of the most
important causes of TEN. The death of keratino-
cytes due to apoptosis is currently thought to be the
major mechanism that leads to TEN.4 Involvement
of the respiratory, gastrointestinal and hemato-
logic systems, as well as the liver and kidneys, are
potential complications of TEN.3 TEN patients
should be treated in a burn center or intensive
care unit. No optimal treatment for SJS and TEN
has been developed. But recently, intravenous
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immunoglobulin (IVIG) has been suggested for
patients with TEN.
Case Report
The patient, a 26-year-old male, was admitted to
the psychiatric department due to acute schiz-
ophrenic agitation. At that time, the patient and
his family gave no history of previous adverse or
allergic drug reactions.
The patient was treated with carbamazepine
200 mg twice daily to control his agitation. Four
days later, he developed erythematous papules,
bullae, and skin erosions. Dermatologic and in-
fectious disease consultations were obtained, and
the diagnosis of SJS was considered. The patient
was transferred to our burn center due to the
progressive nature of his skin eruption.
In the burn center, the patient developed a
high spiking fever. On physical examination, his
blood pressure was 160/100 mmHg, his pulse rate
was 124/min, his respiratory rate was 22/min,
and his body temperature was 39.8°C. Chest aus-
cultation was normal. Bilateral nonpurulent con-
junctivitis was observed; an ophthalmologist was
consulted and topical antibiotics were given. The
patient had erosions and bullae involving the
entire buccal mucosa, tongue and lips, as well as
a painful, generalized, erythematous maculopapu-
lar eruption, with crusts and separation of the
skin on his face, oral cavity, neck, trunk, all four
limbs, and the genital region; Nikolsky’s sign was
present (Figure 1). Some of the skin lesions had
a targetoid appearance. The nail region was also
destroyed and shed (Figure 2). More than 90%
BSA was involved. Skin biopsy from the right
thigh showed total epidermal destruction and
perivascular lymphocytic infiltration (Figure 3).
The diagnosis of TEN was made. The patient’s in-
formation was provided to a medical center in
Taiwan that maintains a database of drug-related
skin disorders, and we obtained his past medical
records from 5 years ago. At that time, the patient
had developed a painful, erythematous eruption
with blister formation on the face, trunk, and all
four limbs after 3 days of carbamazepine treat-
ment. Skin biopsy showed a typical pathologic
feature of SJS. The patient’s carbamazepine was
discontinued immediately. Intravenous hydro-
cortisone (100 mg 4 times daily) and conservative
treatment were given for 6 days. The patient’s con-
dition improved gradually, and he was discharged
without any complications.
Given this past history, the patient was again
given intravenous hydrocortisone (200 mg 4 times
daily). However, a larger area of skin became in-
volved, about 95% BSA, within 3 days. The patient
was intubated due to respiratory distress and acute
Figure 1. Toxic epidermal necrolysis with generalized epider-
mal sloughing involving more than 90% body surface area.
Figure 2. Nail shedding (nail detachment), an uncommon
skin complication of toxic epidermal necrolysis.
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pulmonary edema. The necrotic epidermis was
debrided and covered with sterile biological ma-
terial. The patient developed a high spiking fever,
rapidly progressive renal function deterioration,
and gastrointestinal tract hemorrhage; the patient
died 5 days after being admitted to the intensive
care unit due to multiple organ failure.
Discussion
There are several causes of SJS and TEN, but
drugs appear to be the most common. However,
in some SJS patients, infections, malignancy, and
other autoimmune disease may be the cause,
while TEN is almost always drug-induced.1 More
than 100 different kinds of drugs have been re-
ported to cause SJS and TEN.2 In Taiwan, carba-
mazepine, phenytoin and allopurinol have been
strongly associated with SJS and TEN.5,6
The clinical profile of TEN commonly consists
of a prodrome, an acute stage, and a re-
epithelialization (recovery) stage.1,3 Upper respira-
tory tract infection symptoms, such as fever (100%
of cases), malaise, myalgia, arthralgia, cough, and
anorexia may present 2–3 days before the skin
lesions appear. In addition, other symptoms may
also occur in the prodromal phase, including
conjunctivitis (32% of cases), pharyngitis (25%
of cases), and pruritus (28% of cases).7 The acute
stage of TEN lasts for 8–12 days and is characterized
by rapid spreading epidermal necrosis. Within
2–3 days, the involved skin becomes denuded;
the involved area may be very large and can include
the entire skin surface area. The general appear-
ance is that of a second-degree burn.8 Mucosal
involvement can also occur, involving pharyngeal,
tracheal, bronchial, gastrointestinal, vaginal, anal,
and perineal regions. The re-epithelialization pe-
riod may take 3–6 weeks. Pulmonary involvement
can lead to pulmonary edema, pulmonary em-
bolism, and respiratory failure; mechanical ven-
tilation may be required.9 Approximately 10% 
of patients develop hepatitis, and 50% of TEN
patients have elevated serum aminotransferase
levels.3 Acute tubular necrosis and prerenal azote-
mia are the most common renal problems; they
result from hemodynamic instability.7,10
At present, the mechanisms by which SJS and
TEN develop are not well understood. Recent stud-
ies have found that exposure to causative drugs
can trigger the production of an apoptotic ligand
named CD95 (Fas) ligand. CD95-mediated ker-
atinocyte apoptosis likely plays an important
part in the pathogenesis of TEN.4 In addition to
the CD95 system (CD95L and CD95R), tumor
necrosis factor-α (TNF-α) has been reported to
play an important role in the apoptotic pathway
A B
Figure 3. (A) Histopathology of toxic epidermal necrolysis shows detached extensively necrotic epidermis (hematoxylin &
eosin, 200×). (B) The denuded dermis with sparse mononuclear and eosinophilic infiltration (hematoxylin & eosin, 400×).
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that is triggered in TEN.4,11 In 2004, a genetic
marker, the human leukocyte antigen HLA-B*
1502, was reported to be strongly associated with
carbamazepine-induced SJS (CBZ-SJS) or TEN in
Han Chinese.12 There are no universally accepted
diagnostic criteria for TEN. An international clin-
ical classification defined TEN as the presence of
widespread blisters arising on macules and/or
flat atypical targets or blisters arising from con-
fluent erythema with epidermal detachment of
more than 30% of the skin.13
On skin biopsy, TEN is characterized by wide-
spread necrotic keratinocytes, sparse perivascular
lymphocytic infiltration and full-thickness epi-
dermal necrosis with sloughing from the dermal–
epidermal junction. Immunohistochemical stud-
ies revealed that CD8+ T lymphocytes predominate
in the epidermis, whereas CD4+ T lymphocytes
predominate in the dermis.14
Currently, there is no ideal treatment protocol
for TEN. Early withdrawal of the causative drug
may decrease the mortality of TEN patients.15
The early referral of TEN patients to a burn center
for critical care and appropriate wound manage-
ment can significantly decrease the mortality rate
and improve outcomes.16,17 The use of systemic
corticosteroids is very controversial and a con-
sensus has not been reached thus far.3,18,19 High-
dose IVIG therapy can inhibit CD95-mediated
keratinocyte apoptosis and, therefore, is thought
to be able to successfully treat TEN patients.20
However, Bachot et al’s prospective noncompar-
ative study showed that IVIG therapy did not 
reduce mortality rate or decrease disease progres-
sion.21 IVIG therapy has nephrotoxic effects and
is contraindicated in patients with pre-existing
renal failure and the elderly.22 Other specific
therapies, such as plasmapheresis, thalidomide,
cyclosporine, pentoxifylline, and anti-TNF-α anti-
bodies, have been reported to be effective in small
case series.
The SCORTEN system, an SJS/TEN-specific ill-
ness severity score, has been widely used to pre-
dict the mortality rate of TEN patients. It is based
on seven independent risk factors (age > 40 years;
the presence of malignancy; BSA > 10%; blood
urea nitrogen > 28 mg/dL; blood sugar > 252 mg/
dL; HCO3− < 20 mmol/L; heart rate > 120 beats/
min) evaluated within 24 hours after admission.23
A higher score is associated with a higher mortal-
ity rate and a worse outcome. Our patient’s labo-
ratory data obtained during his SJS and TEN
episodes are presented in Table 1. The SCORTEN
scores of these two episodes were determined
(Table 2). The patient was given the same drug
(carbamazepine) both times, but the degree of his
cutaneous reaction was greater with the second
exposure when he developed TEN. The SCORTEN
score was also much greater on second exposure
(5) than on first exposure (0). The expected mor-
tality rate based on the SCORTEN score also 
increased from 3.2% for the SJS episode to more
than 90% with the TEN episode. The second epi-
sode progressed rapidly despite adequate treat-
ment. The administration of carbamazepine a
second time did not result in another episode of
SJS with a low morbidity and mortality rate, but
Table 1. Patient’s laboratory data on Day 1 in his
SJS and TEN episodes
SJS TEN
Complete blood cell count
White blood cell (×103/µL) 6.0 1.35
Differential count (%)
Neutrophils 62.4 57.5
Lymphocytes 33.2 35.6
Eosinophils 2.2 1.5
Hemoglobin (g/dL) 15.6 12.7
Hematocrit (%) 41.8 36.9
Platelets (×103/µL) 280 99
Serum biochemistry
AST (U/L) 16 1411.5
ALT (U/L) 20 340.28
BUN (mg/dL) 16 30.2
Creatinine (mg/dL) 0.9 4.35
Glucose (mg/dL) 85 286
Arterial blood gas
Blood pH 7.469 7.434
PaCO2 (mmHg) 34.3 27.7
PaO2 (mmHg) 98.4 64.3
Bicarbonate (mmol/L) 24.3 18.1
Oxygen saturation (%) 99.4 93.5
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in a fatal episode of TEN with a SCORTEN of 5.
It is important to note that carbamazepine re-
administration should be avoided in patients with
a previous history of SJS because it may lead to
fatal TEN. Thus, carbamazepine should be used
with caution if the patient’s previous drug his-
tory is not available or the patient has factors
that may predispose him to have an adverse skin
reaction to carbamazepine.
Since 2005, doctors in Taiwan can record a
patient’s adverse drug effects on the National Heath
Insurance identity card. Use of this card could
prevent patients being given drugs to which they
had previously had adverse reactions, even if the
patients or their family cannot provide reliable
information.
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